<DOC>
	<DOCNO>NCT01464931</DOCNO>
	<brief_summary>The primary objective evaluate incidence clinically significant hypocalcemia follow multiple 120 mg subcutaneous dos denosumab patient severe chronic kidney disease ( CKD ) CKD dialysis</brief_summary>
	<brief_title>Multiple Dose Study Evaluate Safety Multiple Doses Denosumab 120 mg Adults With Severe Chronic Kidney Disease ( CKD ) CKD Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Subjects least 18 year old severe CKD ( define creatinine clearance &lt; 30 mL/min screen assessment ) CKD require hemodialysis Additional inclusion criterion apply Subjects must calcium , phosphate , magnesium level appropriate condition must uncontrolled comorbidities . Additional exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>